The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Incyte; Kite, a Gilead company; Seagen
Research Funding - Celgene (Inst); genentech (Inst); Millennium (Inst); Seagen (Inst)
 
Maria Lia Palomba
Consulting or Advisory Role - Juno Therapeutics (I); Pharmacyclics
 
Leo I. Gordon
Patents, Royalties, Other Intellectual Property - Zylem
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Juno Therapeutics; Pharmacyclics; Seagen; TG Therapeutics
 
Jon E. Arnason
Consulting or Advisory Role - Gilead Sciences
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Michael Wang
Honoraria - Celgene; Janssen Oncology; Pharmacyclics
Consulting or Advisory Role - Acerta Pharma; Asana Biosciences; Janssen Oncology
Research Funding - Acerta Pharma; Asana Biosciences; BeiGene; Celgene; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Novartis; Onyx; Pharmacyclics
Travel, Accommodations, Expenses - Acerta Pharma; Janssen Oncology; Kite, a Gilead company
 
Tina M. Albertson
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics; Seagen
Patents, Royalties, Other Intellectual Property - Seagen
 
Tara Allen
Employment - Dendreon; Juno Therapeutics; KinDex (I); Valeant/Dendreon
Stock and Other Ownership Interests - Dendreon; Juno Therapeutics
Travel, Accommodations, Expenses - Dendreon; Juno Therapeutics; KinDex (I)
 
Claire Sutherland
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
Benhuai Xie
Employment - Astellas Pharma (I); Juno Therapeutics; Seagen (I); Takeda
Stock and Other Ownership Interests - Astellas Pharma (I); Juno Therapeutics; Takeda
 
Jacob Garcia
Employment - Amgen; Juno Therapeutics
Stock and Other Ownership Interests - Amgen; Juno Therapeutics
 
Tanya Siddiqi
Speakers' Bureau - Pharmacyclics; Seagen
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company